Physician profile
Marcus Pace
NPI 1083017081
$5,924.85
in general payments reported to CMS, 2019-2025
25 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,365 · 2022: $1,440 · 2023: $1,786 · 2024: $908 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.52 |
| Education | $256.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,882.49 | 2021-2025 | |
| Janssen Biotech, INC. | $711.93 | 2021-2025 | Tremfya, Remicade, Simponi |
| Sun Pharmaceutical Industries INC. | $504.81 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $410.64 | 2022-2024 | Sotyktu |
| Organogenesis INC. | $376.31 | 2023 | Puraply |
| Amgen INC. | $354.76 | 2021-2024 | Otezla, Enbrel |
| Ucb, INC. | $335.99 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $233.05 | 2021-2024 | |
| Lilly USA, LLC | $200.68 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $140.89 | 2021-2023 | Adbry |
| Merz North America, INC. | $117.65 | 2022 | |
| Galderma Laboratories, L.P. | $99.33 | 2021-2022 | |
| Pfizer INC. | $94.83 | 2022-2023 | |
| Almirall LLC | $91.09 | 2021-2025 | Seysara |
| Dermavant Sciences, INC. | $81.02 | 2023-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $76.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $44.70 | 2023-2024 | |
| Organon LLC | $37.11 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2023 | Spevigo |
| Dermira, INC. | $20.41 | 2021 | |
| Glaxosmithkline, LLC. | $20.16 | 2022 | |
| Allergan, INC. | $19.98 | 2022 | |
| Mayne Pharma Commercial LLC | $16.81 | 2021 | |
| Smith+Nephew, INC. | $16.77 | 2022 | |
| Journey Medical Corporation | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.